Nine patients with chronic posterior endogenous uveitis of varying aetiology, not satisfactorily controlled with systemic corticosteroids alone, were treated with low dose oral Cyclosporin A (mean maintenance dose 4.0 ± 1.1 mg/kg/day). Six of the nine patients also continued to receive oral prednisolone (15 mg/day or less). During a follow up period of 6-30 (mean 17) months, seven have shown sustained visual improvement. Nephrotoxicity was the major side effect with serum creatinine con centration (mean ± ISD) rising from 91±7 I-lmoIlI to 115± 13l-lmol/1 (0.01 <p<0.05) after the first twelve months of treatment. Other observed side effects have included taste disturbance, hypomagnesaemia, and hypertension.
Chronic posterior uveitis is a significant cause of visual handicap in young and middle-aged adults, 1 which often requires treatment with systemic corticosteroids or more powerful immuno-suppressive therapy. Cyclosporin A, a cyclic undecapeptide of fungal origin, which inhibits the production of interleukin-2 thereby inhibiting helper T-cell function, has been shown to be of value in both clinicaF·3 and experimental4-6 studies of posterior uveitis. Other ocular conditions in which Cyclosporin A may be of clinical value include Mooren's ulcer,7 Beh«et's disease, 8.9 Graves' ophthalmopathy,IO-12 and corneal graft rejec tion.13,14 Considerable disquiet remains about the potential for toxicity of Cyclosporin A in these non life-threatening situations, notably nephrotoxicity, hepatotoxicity, and the risk of neoplasia with long-term treatment.15. 16 We describe our experience of low dose Cyclosporin A (CsA) treatment in nine patients with sight-threatening chronic intra ocular inflammation which had not been adequately controlled with systemic corticosteroids.
Patients and Methods

Study Group
Clinical details of the study group are shown in Table I . Pars planitis and retinal vasculitis with associated cystoid macular oedema were the most common diseases Treatment was commenced as a single oral dose of 10 mg/kg/day in the first four patients, but the induction dose was subsequently reduced to 5 mg/kg/day because of high whole blood levels. The maintenance dose, taken as a single oral dose in the evening, was there after adjusted to achieve a trough whole blood level of 300-800 ng/ml to minimise nephrotox icity. Trough whole-blood levels of CsA were measured using a radioimmunoassay kit pro vided by Sandoz Ltd. The polyclonal anti CsA antibody could not distinguish between the parent compound and certain of its meta bolites. CsA levels were measured at weekly intervals until stable and monthly thereafter. Patients were initially seen weekly following induction of CsA treatment in hospital and thereafter on a monthly basis.
Results
Clinical Response to CsA
Vision improved in eleven eyes, deterio rated in three, and remained static in one (Fig.  1) . The intraocular inflammatory score showed no significant difference in visual out come between patients receiving combination therapy of CsA and prednisolone or CsA alone. Three eyes were excluded from analy sis for the following reasons: one eye blind following rhegmatogenous retinal detach ment, one eye densely amhlyopic since child hood, and one eye with no clinical evidence of intraocular inflammation throughout the study. Two cases illustrate the benefit of CsA therapy. A 48 year old man with bilateral chronic posterior and anterior uveitis due to sar coidosis, proven by Kveim test, showed a ( Figure 4) A 48 year old man with known Behl<et's disease developed scleritis of his left eye, asso ciated with vitritis and cystoid macular oedema. His scleritis would consistently reac tivate on reducing his dose of prednisolone below 20 mg/day, and he was, therefore, com menced on combination CsA and pred- nisolone therapy with a maintenance dose of esA of 2.75 mg/kg/day. His left visual acuity has improved from 6/60 to 6/12, the intra ocular inflammatory score fallen, and serum creatinine fluctuated between 120-160 Ilmol/l (Fig. 4) . His dose of prednisolone has sub sequently been reduced to 9mg/day.
Cyclosporin A Toxicity
The side effects of treatment are shown in Table III . Nephrotoxicity was the most com mon toxic effect, as evidenced by the gradual rise in serum creatinine over the first 18 months which was significant (0.01 <p<0.05) after 12 months (Fig. 5) . Reductions of other parameters of renal function including lithium clearance which reflects renal tubular dys function were also observed during this period (unpublished observations). Hypomag nesaemia was usually transient with only one patient requiring oral supplements for the treatment of troublesome cramps. Two patients required treatment for hypertension developing after institution of esA therapy. One patient already receiving nifedipine, atenolol, and bendrofluazide therapy for hypertension and who had shown no impair ment of control of her hypertension recently suffered a cerebellar infarct. One man devel oped an erythematous, macular rash resem bling pityriasis versicolor and nail thickening, particularly of the toes, suggesting fungal disease though skin scrapings and nail clip pings failed to demonstrate any pathogenic fungi. In addition, one patient has developed Type II diabetes mellitus, more likely due to obesity and concurrent administration of a thiazide diuretic than any diabetogenic effect of esA.l? Increased hair growth was noted by four patients, but has been troublesome in only one woman. Overt hepatotoxicity has not been observed.
Discussion
The results of this study confirm previous clinical reports of the value of esA in the management of chronic intraocular inflam mation. The overall clinical visual improve ment contrasts with the lack of change in the intraocular inflammatory score in both the anterior and posterior segments of the eye. Anterior uveitis developed in two patients only after the introduction of esA therapy, and, in a further four patients, control of anterior chamber activity necessitated the intermittent use of topical corticosteroids. This observation is at odds with the findings of Nussenblatt and colleagues2 who noted a decrease in the cellular activity in both the anterior chamber and vitreous. Binder et al. 9 also noted a reduction in intraocular inflam mation, though their scoring system did not include the anterior segment of the eye. 18 This discrepancy may reflect the difficulty of accurately measuring intraocular inflam mation, though some further refinements on Hogan and Kimura's systeml9,20 have been made.21
Nephrotoxicity remains the most serious problem, despite a lower maintenance dose than that employed in other studies. Palestine et al. 22 have demonstrated significant renal histopathological changes in a similar group of patients but who had received a maintenance esA dose of 10 mg/kg/day over a period of 24 months. Svenson et al. 23 however, have shown similar histopathological changes in esA treated patients with autoimmune disease (two with uveitis) in whom a lower mainten ance esA dose of 2.5-7.5 mg/kg/day was employed. The latter group have suggested that the cumulative dose of esA may be an important factor in determining nephrotox icity, and this is supported by Klintmalm et al. 24 who reported that in esA treated renal allograft patients maintenance esA doses of 2.3-10.7 mg/kg contributed little to renal damage which was better correlated with high cumulative dosage in the first six months of treatment. Only one patient in our group has temporarily discontinued CsA therapy, but it was gratifying to note that his serum creatinine returned to within the reference range, along with improvement in other para meters of proximal renal tubule function, including enzymuria and proteinuria. The use of divided daily doses of CsA may be a less nephrotoxic regimen than single daily dosage due to lower peak levels but it is associated with a much higher incidence of gingival prob lems,9 which were seen in only one patient in this series. Combination therapy of CsA and cortico steroids has been shown to be of benefit in ophthalmic Graves' Disease.11.12 Kahaly et at. II found combination therapy more success ful than prednisone alone, whereas Utech et al. 12 found combination therapy more success ful than CsA alone. Both studies employed a similar induction dose as this study, but the maintenance doses were not reported. Any change in renal function returned to normal upon cessation of CsA therapy. It is interest ing to note that the two patients in our study who required antihypertensive therapy also received CsA and prednisolone in combina tion as did four subjects in Kahaly's group who subsequently developed hypertension. Further study is required to determine whether hypertension is a more significant adverse effect of combination therapy with oral corticosteroid than CsA therapy alone. Both patients who had ocular sarcoidosis in this series demonstrated improvement in visual acuity and control of intraocular inflam mation which contrasts with the lack of efficacy of CsA noted in pulmonary sarcoidosis. 25 No patient in our study has discontinued CsA therapy because of toxicity, although the dosage has required modification. The fre quency of relapse remains to be established on cessation of therapy and several patients are now tailing off by monthly decrements of 50 mg. Binder et at. 9 noted a high frequency of recurrence of Beh"et's disease activity on reducing the CsA dose below 7 mg/kg/day, and, more worryingly, the severity was often greater than prior to CsA treatment. Whether maintenance of a longer period of quiescence of disease activity by CsA treatment will reduce the frequency of relapse or not has yet to be evaluated.
Low-dose CsA treatment, either as mono therapy or in combination with oral cortico steroids « 15 mg prednisolone), has proved to be of visual benefit in our group of patients with severe chronic intraocular inflammation which had responded poorly to conventional therapy. Nephrotoxicity is the major dose limiting side effect and further study of its aetiology, monitoring, and reversibility is required. 
